Publication at First Faculty of Medicine |
2018
Abstract
Concept of idiopathic pulmonary fibrosis treatment has changed significantly throughout the past decade partially because of existence of effective treatment, on top of complex diagnostic programs. Pirfenidon was the first antifibrotic drug approved for idiopathic pulmonary fibrosis treatment.
Clinical studies proved, that pirfenidon slowed decline of lung functions and decreased mortality of idiopathic pulmonary fibrosis patients. Side effects of the drug are managable and can be tolerated by most patients.
Pirfenidon treatment significantly improves survival of idiopathic pulmonary fibrosis patients (meanly 2,5 years). Both pirfenidon and nintedanib have become the pillars of modern antifibrotic era.